Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation
Active, not recruiting · NCT07817225 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, pancreatic neuroendocrine tumor | Active, not recruiting | Not stated | 2026-09-16 | NCT07817225 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massimo Falconi | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| IRCCS San Raffaele | Milan | Italy | 2 |